Alkermes plc (ALKS) News Headlines

▮ More

Date

Headline

2/14/2019 7:39:50 AM Alkermes Guides FY19 Revenues Higher Than Estimates - Quick Facts

2/14/2019 7:29:07 AM Alkermes plc Q4 adjusted earnings Beat Estimates

2/14/2019 7:16:45 AM Alkermes Q4 Non-GAAP EPS $0.34 Vs $0.31 Last Year

12/24/2018 5:13:44 AM Biotech Stocks Facing FDA Decision In January 2019

12/17/2018 7:47:55 AM Alkermes Submits NDA For Diroximel Fumarate - Quick Facts

12/17/2018 7:31:58 AM Alkermes, Biogen Announce Submission Of NDA To FDA For Diroximel Fumarate In Multiple Sclerosis

11/29/2018 7:08:10 AM Alkermes Reports Positive Topline Results From Phase 3 Study Of ALKS 3831

11/29/2018 7:01:46 AM Alkermes Says ALKS 3831 Met Both Co-Primary Endpoints

10/29/2018 2:55:33 AM Biotech Stocks Facing FDA Decision In November

10/23/2018 7:41:49 AM Alkermes Boosts FY18 Adj Earnings, Revenue Outlook - Quick Facts

10/23/2018 7:15:22 AM Alkermes plc (ALKS) Has Raised Its FY18 Revenue Estimate To $1015 - $1045 Mln From $975 - $1025 Mln

10/23/2018 7:13:48 AM Alkermes plc Q3 adjusted earnings Beat Estimates

10/23/2018 7:02:58 AM Alkermes Plc Q3 Net Loss Narrows To $34.4 Mln Or $0.22/shr From $36.3 Mln Or $0.24/shr Last Year

10/17/2018 7:02:38 AM Alkermes Announces Presentation Of 10 Posters At Upcoming 31st Annual Psych Congress

9/10/2018 7:09:15 AM Alkermes Expands Phase 1 Study For ALKS 4230 In Combination With KEYTRUDA

9/10/2018 7:01:56 AM Alkermes Initiates Clinical Evaluation Of ALKS 4230 In Combination With PD-1 Inhibitor Pembrolizumab

7/26/2018 8:07:06 AM Alkermes plc Q2 adjusted earnings Beat Estimates

7/26/2018 7:07:24 AM Alkermes Q2 Loss Per Share $0.21 Vs Loss $0.28 Last Year

7/3/2018 1:44:33 AM FDA Nod For ALKS, TRXC Sees 4-fold Increase In Q2 Revenue, BCLI On Watch

7/2/2018 7:02:33 AM Alkermes: FDA Approves ARISTADA INITIO For Initiation Of ARISTADA For Schizophrenia

Alkermes Plc (ALKS)